Roche’s Oral SERD Achieves Progression-Free Survival Milestone in Pivotal Breast Cancer Trial

Roche; oral SERD; giredestrant; progression-free survival; pivotal study; breast cancer; ER-positive; endocrine therapy; Phase III trial; advanced breast cancer

Pfizer’s IBRANCE Demonstrates Significant Efficacy in HR+, HER2+ Metastatic Breast Cancer

IBRANCE (palbociclib), HR+/ HER2+ metastatic breast cancer, Phase 3 PATINA trial, Progression-free survival (PFS), Standard-of-care therapies, Anti-HER2 therapy, Endocrine therapy